Impedimed Ltd (ASX: IPD) Share Price and News
Price
–
Movement
– ( )
(20 mins delayed)
52 Week Range
– - –
1 Year Return
Impedimed Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$68.93 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
2.03 billion
Earnings per share
-0.011
Dividend per share
N/A
Year To Date Return
-25.00%
Earnings Yield
N/A
Franking
-
Share Price
–
Day Change
– ( )
52 Week Range
– - –
Yesterday's Close
–
Today's Open
–
Days Range
– - –
Volume
–
Avg. Volume (1 month)
–
Turnover
–
Impedimed Ltd (ASX: IPD)
Latest News
Share Market News
Impedimed (ASX:IPD) share price bounces on 'significant' hospital finding
Share Market News
The Impedimed (ASX:IPD) share price rocketed 13% today. Here's why
Share Market News
Why the Impedimed (ASX:IPD) share price shot higher this morning
Share Market News
Why the Impedimed (ASX:IPD) share price will be on watch today
Share Market News
Here's why the Impedimed (ASX:IPD) share price shot up 13% today
Share Market News
Fund managers have been buying these ASX shares this week
Share Gainers
These ASX small cap shares posted strong gains today
Growth Investing
There 3 under-the-radar healthcare shares could make you rich
Investing
3 shares helping people get better and richer
Investing
Is this medical device stock the next to surge after Cochlear Limited and ResMed Inc.?
Investing
Why these 4 ASX shares have started the week with a bang
Investing
Why these 4 ASX shares have posted strong gains today
Frequently Asked Questions
-
No, Impedimed does not pay shareholder dividends at this time.
-
Impedimed Limited listed on the ASX on 24 October 2007.
IPD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|
About Impedimed Ltd
Impedimed Ltd (ASX: IPD) is a global leader in the design and manufacture of medical devices that use bioimpedance spectroscopy (BIS) technologies in the non-invasive clinical assessment of fluid and tissue composition.
The company's products are typically used to assess and monitor lymphedema and heart failure, as well as to measure patients' tissue composition and fluid status. They also have general health applications in weight management, nutritional issues, and assessing bone content.
As well, Impedimed offers a cloud-based digital platform to manage patient data. The company is based in Australia and generates most of its revenue in North America.
IPD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 02 May 2025 | $0.04 | $0.00 | 0.00% | 2,245,690 | $0.04 | $0.04 | $0.04 |
| 01 May 2025 | $0.04 | $0.00 | 0.00% | 2,450,602 | $0.04 | $0.04 | $0.04 |
| 30 Apr 2025 | $0.04 | $0.00 | 0.00% | 2,277,044 | $0.04 | $0.04 | $0.04 |
| 29 Apr 2025 | $0.04 | $0.01 | 27.78% | 1,520,432 | $0.04 | $0.04 | $0.04 |
| 28 Apr 2025 | $0.04 | $0.00 | 0.00% | 1,781,001 | $0.04 | $0.04 | $0.04 |
| 24 Apr 2025 | $0.03 | $0.00 | 0.00% | 262,257 | $0.03 | $0.04 | $0.03 |
| 23 Apr 2025 | $0.03 | $0.00 | 0.00% | 656,653 | $0.03 | $0.03 | $0.03 |
| 22 Apr 2025 | $0.03 | $0.00 | 0.00% | 3,246,555 | $0.03 | $0.04 | $0.03 |
| 17 Apr 2025 | $0.03 | $0.00 | 0.00% | 3,255,269 | $0.03 | $0.04 | $0.03 |
| 16 Apr 2025 | $0.04 | $0.00 | 0.00% | 879,260 | $0.04 | $0.04 | $0.03 |
| 15 Apr 2025 | $0.04 | $0.00 | 0.00% | 1,195,957 | $0.04 | $0.04 | $0.04 |
| 14 Apr 2025 | $0.04 | $0.00 | 0.00% | 1,036,736 | $0.04 | $0.04 | $0.04 |
| 11 Apr 2025 | $0.04 | $0.00 | 0.00% | 20,000 | $0.04 | $0.04 | $0.04 |
| 10 Apr 2025 | $0.04 | $0.00 | 0.00% | 905,401 | $0.04 | $0.04 | $0.04 |
| 09 Apr 2025 | $0.04 | $0.00 | 0.00% | 2,364,178 | $0.04 | $0.04 | $0.03 |
| 08 Apr 2025 | $0.04 | $0.00 | 0.00% | 1,826,449 | $0.04 | $0.04 | $0.04 |
| 07 Apr 2025 | $0.04 | $0.00 | 0.00% | 2,948,705 | $0.04 | $0.04 | $0.04 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 22 Apr 2025 | Andrew Grant | Issued | 197,647 | $8,399 |
Director remuneration.
|
| 22 Apr 2025 | Christine Emmanuel-Donnelly | Issued | 349,412 | $14,850 |
Director remuneration.
|
| 22 Apr 2025 | Janelle Delaney | Issued | 197,647 | $8,399 |
Director remuneration.
|
| 22 Apr 2025 | Fiona Bones | Issued | 197,647 | $8,399 |
Director remuneration.
|
| 04 Mar 2025 | Christine Emmanuel-Donnelly | Buy | 545,000 | $20,832 |
On-market trade.
|
| 04 Mar 2025 | Christine Emmanuel-Donnelly | Buy | 318,116 | $13,414 |
On-market trade.
|
| 31 Jan 2025 | Christine Emmanuel-Donnelly | Issued | 275,988 | $14,850 |
Director remuneration.
|
| 31 Jan 2025 | Andrew Grant | Issued | 156,115 | $8,400 |
Director remuneration.
|
| 31 Jan 2025 | Fiona Bones | Issued | 156,115 | $8,400 |
Director remuneration.
|
| 31 Jan 2025 | Janelle Delaney | Issued | 156,115 | $8,400 |
Director remuneration.
|
| 23 Dec 2024 | Janelle Delaney | Issued | 152,468 | $8,400 |
Director remuneration.
|
| 23 Dec 2024 | Fiona Bones | Issued | 152,468 | $8,400 |
Director remuneration.
|
| 23 Dec 2024 | Andrew Grant | Issued | 152,468 | $8,400 |
Director remuneration.
|
| 23 Dec 2024 | Christine Emmanuel-Donnelly | Issued | 269,542 | $14,851 |
Director remuneration.
|
| 22 Nov 2024 | Christine Emmanuel-Donnelly | Buy | 295,000 | $15,915 |
On-market trade.
|
| 20 Nov 2024 | Fiona Bones | Buy | 920,000 | $49,276 |
On-market trade.
|
| 16 Oct 2024 | McGregor Grant | Issued | 6,500,000 | $422,500 |
Issue of options.
|
| 16 Oct 2024 | McGregor Grant | Issued | 6,500,000 | $422,500 |
Issue of securities. 6,500,000 Performance Rights
|
| 16 Oct 2024 | Parmjot Bains | Issued | 8,500,000 | $552,500 |
Issue of securities. 8,500,000 Performance Rights
|
| 16 Oct 2024 | Parmjot Bains | Issued | 8,500,000 | $552,500 |
Issue of options.
|
| 05 Sep 2024 | Andrew Grant | Buy | 600,000 | $28,530 |
On-market trade.
|
| 30 Aug 2024 | Andrew Grant | Buy | 1,000,000 | $49,600 |
On-market trade.
|
| 30 Aug 2024 | Christine Emmanuel-Donnelly | Buy | 200,000 | $10,000 |
On-market trade.
|
| 14 May 2024 | Christine Emmanuel-Donnelly | Buy | 100,000 | $8,000 |
On-market trade.
|
| 08 May 2024 | Janelle Delaney | Buy | 634,177 | $50,099 |
On-market trade.
|
| 06 May 2024 | Andrew Grant | Buy | 100,000 | $8,050 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Parmjot Bains | Managing DirectorChief Executive Officer | Jan 2024 |
Dr Bains is a medical doctor with more than 30 years of diverse healthcare experience including Pfizer and McKinsey across the United States, Asia, Middle East and Australia.
|
| Mr Andrew John Grant | Non-Executive Director | Sep 2023 |
Mr Grant has spent more than 20 years in gaining understanding and experience working with key US customers and across global healthcare markets. He has Strategic planning experience and delivery in healthcare working with leading healthcare organisations globally, including McKinsey and ResMed. He is also a member of Risk Committee.
|
| Mr McGregor Grant | Executive DirectorChief Financial Officer | Feb 2024 |
Mr Grant brings Broad commercial and financial experience in growing successful global medical device businesses, most recently Nanosonics Limited. He has Board administration, governance and investor relations experience.
|
| Ms Christine Emmanuel-Donnelly | Non-Executive DirectorNon-Executive Chairman | Sep 2023 |
Ms Emmanuel-Donnelly brings 30 years in IP expertise through commercialisation and strategic in-house intellectual property roles. She has more than 4 years in Board and healthcare governance experience. She is a member of the Risk Committee.
|
| Ms Janelle Delaney | Non-Executive Director | Sep 2023 |
Ms Delaney has 30 years of project management and execution at IBM, with responsibility for the quality of delivery across Asia Pacific's portfolio of several thousand projects. She is a member of Risk Committee.
|
| Ms Fiona Bones | Non-Executive Director | Jun 2024 |
Ms Bones brings more than 30 years of experience in the finance, corporate governance and systems transformation. She has global governance experience gained as Vice President of Finance, International Controller of Google for 20 years. She is Chair of the Risk Committee.
|
| Ms Leanne Ralph | Company Secretary | Jan 2015 |
-
|
| Steven Chen | Chief Medical Officer |
-
|
|
| Leanne Ralph | Company Secretary |
-
|
|
| Ashley Munoz | Director Human Resources |
-
|
|
| Andrew Grant | Executive Director VP Product Development & Customer Solutions |
-
|
|
| Julie Kuhlken | Senior Director Downstream Marketing |
-
|
|
| Dennis Schlaht | SVP R&D and Technology |
-
|
|
| Tim Benkovic | SVP Sales & Customer Success |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 177,180,440 | 8.76% |
| HSBC Custody Nominees (Australia) Limited | 164,419,200 | 8.13% |
| Jp Morgan Nominees Australia Pty Limited | 148,941,253 | 7.36% |
| National Nominees Limited | 115,304,879 | 5.70% |
| HSBC Custody Nominees (Australia) Limited i | 55,570,348 | 2.75% |
| BNP Paribas Noms Pty Ltd | 34,426,377 | 1.70% |
| Sunlora Pty Ltd | 32,125,000 | 1.59% |
| Moore Family Nominee Pty Ltd | 30,000,000 | 1.48% |
| Mr Hamish Alexander Jones | 23,538,705 | 1.16% |
| Mba Investments Pty Ltd | 22,490,990 | 1.11% |
| Mr Gregory Wayne Brown | 20,300,000 | 1.00% |
| Mr Stephen Edward Mahnken & Mrs Dior Leone Mahnken | 19,000,000 | 0.94% |
| Bnp Paribas Nominees Pty Ltd i | 18,925,694 | 0.94% |
| Pakasoluto Pty Limited | 16,011,422 | 0.79% |
| Mr Hsien Michael Soo | 15,662,797 | 0.77% |
| First Samuel Ltd Acn 086243567 | 15,281,508 | 0.76% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 14,251,964 | 0.70% |
| Bsd Pty Ltd | 13,495,000 | 0.67% |
| Hme Soo Holdings Pty Ltd | 12,320,921 | 0.61% |
| Bnp Paribas Nominees Pty Ltd ii | 11,693,112 | 0.58% |